Long-term dupilumab treatment for severe asthma effective in real-world

Patients with severe asthma who receive long-term treatment with dupilumab in real-world settings see sustained improvements in clinical and patient outcomes, with most achieving remission after 2 years, according to interim data of the ProVENT study.

ProVENT is a prospective, noninterventional, 3-year study that involved severe asthma patients aged ≥12 years who received dupilumab in routine clinical care. The interim data included lung function, asthma control, quality of life, biomarkers, and clinical remission over the first 2 years of the study. Safety data will be provided in the final analysis.

A total of 399 patients were enrolled in the study, of which 259 underwent at least one postbaseline assessment and 100 had documented data after 24 months of treatment.

Patients showed improvements in lung function, asthma control, and quality of life through 24 months. The mean change in prebronchodilator forced expiratory volume in 1 s (FEV1) was 0.24 L, while that in the prebronchodilator percent predicted FEV1 was 10.10 percent.

Over 24 months, the mean decrease in the 5-item Asthma Control Questionnaire (ACQ-5) score was 0.96, and the mean increase in the Asthma Control Test (ACT) score was 4.4. The mean change in the Standardized Asthma Quality of Life Questionnaire overall score was 0.61.

Blood eosinophils, fractional exhaled nitric oxide (FeNO), and total serum immunoglobulin E (IgE) decreased by month 24.

Clinical remission occurred in 55.9 percent of patients at year 1. This number increased to 58 percent at year 2.